Key facts
- BioReact’s last known valuation is $5.0M.
- It has raised $1.2M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Plug and Play Tech Center, Techstars, Service Provider Capital, gBETA, FortySix Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for BioReact
- ·The full record, as it builds
Funding rounds
No funding rounds for BioReact are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioReact
Developer of cloud-based artificial intelligence software designed for bioprocess development and optimization. The company's products are used for parameter optimization and focus on automating tasks and improving efficiency within the bioprocess development field, automatically aligning online and offline data from virtually every bioreactor and offline data source, enabling scientists to accelerate process optimization and scale-up.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2023
- Employees
- 5
- Website
- bioreact.co/
- Ownership
- Privately Held (backing)
BioReact doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioReact shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioReact in its N-PORT filings yet. We sweep new filings monthly.